Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Unilateral Knee Arthroplasty Clear all
Recruiting Not applicable Interventional

Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery

NCT06946368
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL, Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL, Local Infiltration Analgesia (LIA) of EXPAREL
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 23, 2026, 2:23 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

NCT03797612
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Brivoligide Injection 660 mg/6 mL, Placebo 6 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Sheffield, Alabama • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

NCT02284386
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine SNB, EXPAREL Infiltration
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Sheffield, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Results available

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

NCT02255500
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine FNB, EXPAREL Infiltration
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 3 Interventional

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

NCT01055015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

NCT00859313
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Sufentanil NanoTab PCA System/15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
45 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Birmingham, Alabama • Vero Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Jul 23, 2026, 2:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Total Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilateral Primary Total Knee Arthroplasty

NCT07672301
View directory record Official record
Conditions
Total Knee Arthroplasty (TKA)
Interventions
Total IntraVenous Anesthesia (TIVA), Spinal-Block, Electroencephalogram (EEG)
Combination Product · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Results available

Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty

NCT01027286
View directory record Official record
Conditions
Arthritis
Interventions
Vitagel
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jul 23, 2026, 2:23 AM EDT
Terminated Not applicable Interventional Results available

Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

NCT04992052
View directory record Official record
Conditions
Total Knee Replacement
Interventions
Bone wax
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Syosset, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

NCT01410240
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis
Interventions
Standard of Care, FLOSEAL Hemostatic Matrix + Standard of care
Procedure · Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Jul 23, 2026, 2:23 AM EDT
Enrolling by invitation Phase 4 Interventional

EXPAREL IPSA Block in Knee Arthroplasty

NCT06619340
View directory record Official record
Conditions
Pain, Postoperative, Osteo Arthritis Knee
Interventions
Exparel
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 23, 2026, 2:23 AM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study on EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block vs. Local Infiltration Analgesia in Knee Replacement Surgery

NCT07584915
View directory record Official record
Conditions
Total Knee Arthroplasty, Total Knee Arthroplasty Recovery
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block with LIA, Local Infiltration Analgesia (LIA), Bupivacaine liposome injectable suspension (IPSA block), Bupivacaine liposome injectable suspension (LIA)
Procedure · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Not applicable Interventional

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

NCT00419276
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Ambulatory continuous femoral nerve block for 100 hours
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Berkeley, California • San Diego, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 23, 2026, 2:23 AM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
La Mesa, California • Rancho Mirage, California • Lone Tree, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:23 AM EDT
Terminated Phase 4 Interventional

ZYNRELEF for Pain Management in Total Knee Arthroplasty

NCT05644496
View directory record Official record
Conditions
Post Operative Pain, Osteoarthritis, Knee
Interventions
Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
35 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Preoperative N1539 in Total Knee Arthroplasty

NCT03434275
View directory record Official record
Conditions
Pain, Postoperative
Interventions
N1539, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
35 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Florence, Alabama • Mobile, Alabama • Sheffield, Alabama + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

NCT00818493
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Not applicable Interventional Results available

Conventional Alignment System Versus Surgical Navigation System in Total Knee Arthroplasty

NCT01797731
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Digital hand-held surgical navigation system, Conventional tibial extramedullary alignment system
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 23, 2026, 2:23 AM EDT
Suspended Phase 2Phase 3 Interventional

Safety of F14 Following Total Knee Replacement

NCT04860635
View directory record Official record
Conditions
Analgesia
Interventions
F14 (sustained release celecoxib)
Drug
Lead sponsor
Arthritis Innovation Corporation
Industry
Eligibility
45 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
2
States / cities
Denver, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

NCT00612534
View directory record Official record
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab, Placebo NanoTab
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
45 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02807428
View directory record Official record
Conditions
Post-surgical Pain
Interventions
AYX1 Injection 660 mg/6 mL, Placebo Injection 6 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 23, 2026, 2:23 AM EDT
Completed Not applicable Interventional

ROMTECH PortableConnect Rehabilitation Device Usage Post Unilateral Total Knee Arthroplasty (TKA)

NCT04497129
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic, Knee Disease, Joint Pain, Osteo Arthritis Knee, Osteoarthritis, Knee
Interventions
ROMTech PortableConnect, Traditional Rehabilitation and CPM Device
Device
Lead sponsor
ROM Technologies, INC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Aventura, Florida • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 23, 2026, 2:23 AM EDT